Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Neurotoxin, widely used to produce the 6-OHDA Parkinson’s disease model
Purity:>98%
ABT 724 trihydrochloride (HB1883)
Description:Potent dopamine D4 receptor partial agonist
Purity:>99%
Acamprosate calcium (HB0099)
Description:GABA receptor agonist and glutamatergic modulator
Purity:>98%
Alprenolol hydrochloride (HB1734)
Description:Non-selective β-adrenoceptor antagonist. Also a 5-HT1A receptor antagonist.
Purity:>99%